Laborda and colleagues designed an scFv-based CLL1 CAR that showed cytotoxic activity against HL60 and MOLM14 AML cell lines and patient-derived AML blasts in vitro, as well as clearance against tumor cells in mouse xenografts, while without damaging healthy HSCs. Here, CLEC12A is linked to acute myeloid leukemia.